Evaluation of response to various erythropoiesis - Stimulating proteins using anemia management software

Journal of Renal Care

Volumn 33, Issue 2, 2007, Pages 78-82

  Waterschoot, Marcia ^a  

^a OLV HOSPITAL   (Belgium)

Author keywords

Anaemia management; Chronic kidney disease; Erythropoiesis; Hyporesponse; Iron deficiency

Indexed keywords

EID: 34547119550     PISSN: 1019083X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-6686.2007.tb00045.x     Document Type: Article

References (9)

1. MacDougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 2002; 17 [suppl 11]: 39-43.
2. EPREX® (epoetin alfa) Summary of product characteristics 2002, Janssen-Cilag N.V. 2600 Berchem, Belgium.
3. NeoRecormon® Summary of product characteristics 2002. Roche Registration Ltd., Hertfordshire AL7 3AY, UK.
4. ARANESP® (darbepoetin alfa). European Union summary of product characteristics 2002. Amgen Europe B.V., 4817 ZK Breda, The Netherlands.
5. EBPG European Best Practice Guidelines. Nephrol Dial Transplant 1999; 14 [suppl 5]: 5-32.
6. Alijama P, Bommer J, Canaud B et al. (The NESP Usage Guidelines Group). Practical guidelines for the use of NESP in treating renal anaemia. Nephrol Dial Transplant 2001, 16 [suppl 3]: 22-8.
7. Locatelli, F., et al., Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 [suppl 2]: ii1-47.
8. Jacobs C, Frei D, Perkins AC. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol Dial Transplant 2005; 20 [suppl 3]: iii3-24.
9. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 94-111.